STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

LGND LIGAND PHARMACEUTICALS INCORPORATED StockScouter® Report

3

StockScouter® Score

LIGAND PHARMACEUTICALS INCORPORATED, a small cap growth company in the healthcare sector, is expected to underperform the market over the next six months with average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • Short-term relative price momentum exhibits moderate strength. Postive/Neutral

 

Concerns

  • The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
  • One or more analysts has significantly decreased quarterly earnings estimates for LGND. Negative
  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that small cap stocks will be in favor, growth stocks will be in favor, and healthcare stocks will be in favor.

Expected Risk/Return

Progress: 60% done.
Progress: 20% done.
Low
High

Core Model Grades

D
C
F
D

Previous Ratings

5
5
5